Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Metastasis02:30

Metastasis

6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SERS detection of osteoarthritis-linked microRNA-204 via a DNAzyme-catalyzed self-amplifying circuit.

Journal of pharmaceutical analysis·2026
Same author

Development of a CD9 aptamer for liquid biopsy of extracellular vesicles.

Archives of biochemistry and biophysics·2026
Same author

Dual-site spatiotemporal and simultaneous inhibition on PIN1 via arsenic-retinoic albumin nanoparticles enables synergistic oncotherapy.

Journal of nanobiotechnology·2025
Same author

Structure-based discovery of forsythoside A as an effective inhibitor to reduce the neurotoxicity of amyloid β.

Communications chemistry·2025
Same author

Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers.

Molecular systems biology·2025
Same author

TGF-β secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation.

Journal of Cancer·2025

Related Experiment Video

Updated: Jan 2, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K

Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy.

Shu Lian1, Xiaodong Xie1, Yusheng Lu1,2

  • 1Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, People's Republic of China.

Oncotargets and Therapy
|December 7, 2019
PubMed
Summary

CD47, a protein on tumor cells, helps cancers evade immune detection and spread. Targeting CD47 shows promise for cancer immunotherapy and diagnosis, especially with combined therapies.

Keywords:
CD47biological targetimmune checkpointimmune therapy

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.1K

Related Experiment Videos

Last Updated: Jan 2, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.1K

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Cancer immunotherapy leverages immune checkpoints to eliminate cancer cells.
  • CD47 (cluster of differentiation 47) is a cell surface glycoprotein acting as an inhibitory receptor.
  • High CD47 expression on tumor cells and exosomes facilitates immune evasion and metastasis.

Purpose of the Study:

  • To review the multifaceted role of CD47 in tumor metastasis.
  • To explore CD47's function in immune evasion by cancer cells.
  • To provide insights into CD47-targeted immunotherapeutic strategies.

Main Methods:

  • Literature review of studies on CD47 in cancer.
  • Analysis of CD47's interaction with SIRP-α (signal regulatory protein alpha).
  • Examination of CD47's role in exosome-mediated tumor spread and cell migration.

Main Results:

  • CD47 interaction with SIRP-α allows cancer cells to escape macrophages and T cells.
  • High CD47 expression on tumor cells, circulating tumor cells (CTCs), and exosomes correlates with increased metastasis and immune evasion.
  • CD47 targeting, in combination with other biomarkers or therapies (e.g., anti-PD-L1, rituximab, nanomaterials), enhances anti-tumor effects.

Conclusions:

  • CD47 is a critical mediator of tumor immune evasion and metastasis.
  • Targeting CD47 offers a promising avenue for cancer diagnosis, prognosis, and treatment.
  • Combined therapeutic approaches involving CD47 modulation show significant potential for improving cancer immunotherapy outcomes.